SCHEMBL20667650

SCHEMBL20667650

C/N=C/c1cc(Oc2ccc(C=O)cc2F)cc(C(F)(F)F)c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.36
POLB P06746 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
TTR P02766 1/20 0.36
MEN1 O00255 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
TSHR P16473 1/20 0.33
GAA P10253 1/20 0.32
KIF11 P52732 1/20 0.32
AOX1 Q06278 1/20 0.31
BRD4 O60885 1/20 0.31
RAB9A P51151 1/20 0.30
TUBB1 Q9H4B7 1/20 0.30
FDPS P14324 1/20 0.30
TLR8 Q9NR97 1/20 0.30
EPAS1 Q99814 1/20 0.30
GCGR P47871 1/20 0.30
AR P10275 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15901064 0.82 EPAS1 (0.41) ALDH1A1POLBL3MBTL1TTRMEN1
SCHEMBL19154290 0.81 AR (0.36) L3MBTL1TTRKIF11EPAS1AR
SCHEMBL15909890 0.78 TTR (0.43) ALDH1A1POLBL3MBTL1TTRTSHR
SCHEMBL875690 0.77 L3MBTL1 (0.59) ALDH1A1POLBL3MBTL1TTRMEN1
SCHEMBL17468303 0.77 EPAS1 (0.45) ALDH1A1POLBL3MBTL1EPAS1AR
SCHEMBL15900890 0.75 ALDH1A1 (0.44) ALDH1A1POLBL3MBTL1TTRMEN1
SCHEMBL19154904 0.74 ALDH1A1 (0.52) ALDH1A1POLBL3MBTL1TTRMEN1
SCHEMBL23247704 0.73 TTR (0.62) ALDH1A1POLBTTRHPGDTSHR
SCHEMBL14663508 0.72 TUBB1 (0.47) ALDH1A1POLBTTRMEN1HPGD
SCHEMBL14656121 0.72 TTR (0.44) ALDH1A1POLBL3MBTL1TTRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10428078-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-10-01 US disclosed
EP-3172211-B1 TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 GLAXOSMITHKLINE IP DEV LTD (GB) 2019-07-03 EP disclosed
US-20190023715-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190023715-A1 COMPOUNDS PLAAT2, PLA2G12A, PLA2G1B ALDH1A1 2222/4885POLB 3233/4885L3MBTL1 3347/4885
US-10428078-B2 Compounds PLAAT2, PLA2G12A, PLA2G1B ALDH1A1 2222/4885POLB 3233/4885L3MBTL1 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.